NEW: We've expanded Stock Detail, Screener, and Maps with new data

Stock Detail, Screener:
3, 5, 10-Year Performance
EV/EBITDA, EV/Sales
Dividend Growth (1, 3, 5 Years)
EPS & Sales Growth (3 Years)

Maps:
All from Screener plus:
ROA, ROE, ROIC
Quick & Current Ratios
LT Debt and Debt to Equity Ratios
Gross, Operating, and Net Margins

Last Close
Jun 30 04:00PM ET
6.80
Dollar change
-0.10
Percentage change
-1.45
%
Index- P/E- EPS (ttm)-18.08 Insider Own8.40% Shs Outstand4.09M Perf Week-0.73%
Market Cap27.79M Forward P/E- EPS next Y-10.38 Insider Trans0.00% Shs Float3.74M Perf Month10.93%
Enterprise Value19.39M PEG- EPS next Q-2.61 Inst Own3.86% Short Float11.75% Perf Quarter-32.25%
Income-44.80M P/S- EPS this Y48.05% Inst Trans-40.54% Short Ratio3.58 Perf Half Y-38.95%
Sales0.00M P/B2.15 EPS next Y-2.45% ROA-117.06% Short Interest0.44M Perf YTD-37.32%
Book/sh3.16 P/C1.29 EPS next 5Y22.92% ROE-282.07% 52W High30.03 -77.36% Perf Year-75.78%
Cash/sh5.26 P/FCF- EPS past 3/5Y41.44% 50.16% ROIC-235.95% 52W Low5.35 27.11% Perf 3Y-77.36%
Dividend Est.- EV/EBITDA- Sales past 3/5Y- - Gross Margin- Volatility3.78% 8.87% Perf 5Y-98.25%
Dividend TTM- EV/Sales- EPS Y/Y TTM-77.89% Oper. Margin- ATR (14)0.55 Perf 10Y-99.99%
Dividend Ex-Date- Quick Ratio1.70 Sales Y/Y TTM- Profit Margin- RSI (14)45.96 Recom3.00
Dividend Gr. 3/5Y- - Current Ratio1.70 EPS Q/Q31.64% SMA20-6.12% Beta-1.93 Target Price108.50
Payout- Debt/Eq1.18 Sales Q/Q- SMA50-2.92% Rel Volume0.49 Prev Close6.90
Employees25 LT Debt/Eq0.71 EarningsMay 13 AMC SMA200-38.06% Avg Volume122.89K Price6.80
IPONov 12, 2012 Option/ShortNo / Yes EPS/Sales Surpr.4.05% - Trades Volume62,242 Change-1.45%
Date Action Analyst Rating Change Price Target Change
Apr-10-25Downgrade Scotiabank Sector Outperform → Sector Perform
Apr-10-25Downgrade H.C. Wainwright Buy → Neutral
Mar-14-24Initiated Scotiabank Sector Outperform $13
Feb-08-24Initiated Jefferies Buy $15
Jun-30-25 08:00AM
Jun-12-25 09:00AM
Jun-11-25 08:00AM
Jun-06-25 11:35AM
Jun-05-25 08:00AM
04:28PM Loading…
May-13-25 04:28PM
Apr-28-25 04:05PM
Apr-21-25 08:00AM
Apr-10-25 11:05AM
Apr-09-25 04:30PM
Mar-27-25 04:10PM
Mar-25-25 04:30PM
Mar-13-25 08:00AM
Feb-10-25 08:00AM
Feb-07-25 04:30PM
08:00AM Loading…
Jan-06-25 08:00AM
Dec-06-24 04:30PM
Dec-05-24 09:00PM
Nov-25-24 04:30PM
Nov-12-24 04:21PM
08:00AM
Oct-10-24 07:01AM
07:00AM
Sep-20-24 04:30PM
Sep-18-24 08:00AM
Sep-05-24 08:00AM
Aug-23-24 04:30PM
Aug-21-24 08:00AM
Aug-15-24 08:00AM
Aug-08-24 04:56PM
08:13AM Loading…
Jun-20-24 08:13AM
08:00AM
07:28AM
Jun-18-24 06:22PM
Jun-07-24 04:30AM
May-21-24 08:00AM
May-09-24 04:29PM
Apr-26-24 04:05PM
Apr-09-24 08:00AM
Apr-04-24 08:00AM
Mar-19-24 09:53PM
04:25PM
Mar-12-24 08:00AM
Mar-05-24 04:30PM
Feb-26-24 08:00AM
Feb-02-24 04:30PM
Jan-05-24 04:05PM
Dec-01-23 04:15PM
Nov-20-23 08:00AM
Nov-08-23 05:17PM
Oct-12-23 08:25AM
Oct-11-23 04:29PM
08:01AM
08:00AM
07:41AM
Oct-10-23 04:05PM
Sep-19-23 08:00AM
Sep-05-23 08:00AM
Aug-10-23 04:13PM
Jul-19-23 08:00AM
May-31-23 04:05PM
May-25-23 05:00PM
May-19-23 04:05PM
May-10-23 04:15PM
Apr-28-23 08:00AM
Apr-27-23 04:58PM
Apr-26-23 06:41PM
Apr-17-23 09:00AM
Mar-22-23 05:26PM
Mar-15-23 04:05PM
Mar-14-23 04:30PM
Nov-22-22 04:05PM
Nov-10-22 09:00AM
Nov-08-22 08:00AM
Nov-02-22 08:00AM
Oct-06-22 08:00AM
Sep-07-22 08:00AM
Aug-15-22 08:00AM
Jul-07-22 08:00AM
Jun-09-22 08:00AM
Jun-06-22 04:05PM
May-26-22 04:57PM
May-13-22 08:00AM
Apr-27-22 10:01AM
08:00AM
Apr-08-22 01:00PM
Mar-29-22 04:00PM
Mar-10-22 08:00AM
Mar-08-22 04:30PM
Feb-09-22 08:00AM
Nov-18-21 08:00AM
Nov-12-21 07:00AM
Nov-10-21 04:05PM
Nov-09-21 08:00AM
Nov-08-21 08:00AM
Oct-01-21 08:00AM
Sep-20-21 08:00AM
Sep-13-21 08:00AM
Sep-09-21 04:01PM
Aug-12-21 04:01PM
Tempest Therapeutics, Inc. is a clinical-stage oncology company advancing a diverse portfolio of small molecule product candidates containing tumor-targeted and/or immune-mediated mechanisms with the potential to treat a wide range of tumors. The company's novel programs range from early research to later-stage investigation in a randomized global study in first-line cancer patients. Tempest Therapeutics was founded in 2011 and is headquartered in Brisbane, CA.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Versant Venture Capital VI, L.OwnerAug 12 '24Proposed Sale1.10387,999426,993Aug 13 08:03 AM
Versant Venture Capital VI, L.10% OwnerAug 08 '24Sale1.35400,000540,040597,940Aug 12 08:33 PM
Versant Venture Capital VI, L.10% OwnerAug 12 '24Sale1.10387,999426,993209,941Aug 12 08:33 PM
Versant Venture Capital VI, L.10% OwnerAug 08 '24Proposed Sale18.03400,0007,210,532Aug 09 03:41 PM
Brady Stephen RPresident and CEOJul 03 '24Buy2.1135,00073,85046,376Jul 08 04:15 PM
Whiting SamuelChief Medical OfficerJul 02 '24Buy2.134,6729,9519,573Jul 03 07:35 PM